Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Webb

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymesJ L Adams, J C Boehm, S Kassis, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
Brain : a Journal of Neurology|August 23, 2006
Inherited prion disease with six octapeptide repeat insertional mutation--molecular analysis of phenotypic heterogeneitySimon Mead, Mark Poulter, Jon Beck, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Neurology|August 22, 2007
Inherited prion disease with 5-OPRI: phenotype modification by repeat length and codon 129S Mead, T E F Webb, T A Campbell, et al.
Journal of Neuropathology and Experimental Neurology|August 22, 2008
First report of Creutzfeldt-Jakob disease occurring in 2 siblings unexplained by PRNP mutationThomas E F Webb, Suvankar Pal, Durrenajaf Siddique, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonistH M Sarau, D E Griswold, W Potts, et al.
The Lancet. Neurology|December 17, 2008
Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association studySimon Mead, Mark Poulter, James Uphill, et al.
Journal of Medicinal Chemistry|December 20, 1996
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)ureaJ L Adams, R S Garigipati, M Sorenson, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2000
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonistH M Sarau, D E Griswold, B Bush, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymesJ L Adams, J C Boehm, S Kassis, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|October 29, 2000
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lungD C Underwood, R R Osborn, S Bochnowicz, et al.
Brain : a Journal of Neurology|August 23, 2006
Inherited prion disease with six octapeptide repeat insertional mutation--molecular analysis of phenotypic heterogeneitySimon Mead, Mark Poulter, Jon Beck, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 29, 2000
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistenceD C Underwood, R R Osborn, C J Kotzer, et al.
Neurology|August 22, 2007
Inherited prion disease with 5-OPRI: phenotype modification by repeat length and codon 129S Mead, T E F Webb, T A Campbell, et al.
Journal of Neuropathology and Experimental Neurology|August 22, 2008
First report of Creutzfeldt-Jakob disease occurring in 2 siblings unexplained by PRNP mutationThomas E F Webb, Suvankar Pal, Durrenajaf Siddique, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 1, 1997
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonistH M Sarau, D E Griswold, W Potts, et al.
The Lancet. Neurology|December 17, 2008
Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association studySimon Mead, Mark Poulter, James Uphill, et al.
Journal of Medicinal Chemistry|December 20, 1996
Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)ureaJ L Adams, R S Garigipati, M Sorenson, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2000
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonistH M Sarau, D E Griswold, B Bush, et al.
Pageof 4